|
|
|
| Current Progress in Stem Cells for Clinical Application and Management Strategies |
| WANG Zhuang, PEI Xue-tao |
| Key Laboratory of Stem Cell and Regenerative Medicine of PLA,Beijing Institute of Transfusion Medicine,Beijing 100850,China |
|
|
|
Abstract Stem cells research and the technology of stem cell-based regenerative medicine have become one of the important parts for the development of biomedicines. The research and development of stem cell and regenerative medicine will have important impacts on the medical market for the patients with tissue and/or organ deficits or dysfunction. Based on the origin and the way obtained,stem cells are classcified as embryonic stem cells(ESCs),induced pluripotent stem cells(iPSCs)and adult stem cells(ASCs). Different types of stem cells may have different characteristics,and different risk potential for clinical use. The products of stem cells may have different clinical indication,and be reviewed by different standards. The current progress in the clinical application and management strategies of stem cells were reviewed
|
|
Received: 10 March 2011
Published: 25 August 2011
|
|
|
|
|
|
[1] Pozzobon M, Ghionzoli M, De Coppi P. ES, iPS, MSC, and AFS cells, stem cells exploitation for pediatric surgery: current research and perspective. Pediatr Surg Int, 2010,26(1):3-10.
[2] Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev, 2010,24(20):2239-2263.
[3] Giralt S A, Horowitz M, Weisdorf D, et al. Review of stem-cell transplantation for myelodysplastic syndrmoes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol, 2011, 29(5):566-572.
[4] Brignier A C, Gewirtz A M. Embryonic and adult stem cell therapy. J Allergy Clin Immunol, 2010,125(2): 336-344.
[5] Joannides A J, Chandran S. Human embryonic stem cells: an experimental and therapeutic resource for neurological disease. J Neurol Sci, 2008,265(1-2):84-88.
[6] Schroeder I S, Rolletschek A, Blyszczuk P, et al. Differentiation of mouse embryonic stem cells to insulin-producing cells. Nat Protoc, 2006,1(2):495-507.
[7] Gonzales C, Pedrazzini T. Progenitor cell therapy for heart disease. Exp Cell Res, 2009,315(18):3077-3085.
[8] Sharp J, Frame J, Siegenthaler M, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells, 2010,28(1):152-163.
[9] Rosenzweig A. Cardiac cell therapy——mixed results from mixed cells. N Engl J Med, 2006,355(12):1274-1277.
[10] Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med, 2006,355(12):1222-1232.
[11] Laguna Goya R, Kuan W L, Barker R A. The future of cell therapies in the treatment of Parkinson's disease. Expert Opin Biol Ther, 2007,7(10):1487-1498.
[12] Deschaseaux F, Pontikoglou C, Sensebe L. Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med, 2010,14(1-2):103-115.
[13] Kisseleva T, Gigante E, Brenner D A. Recent advances in liver stem cell therapy. Curr Opin Gastroenterol, 2010,26(4):395-402.
[14] Gekas C, Graf T. Induced pluripotent stem cell-derived human platelets: one step closer to the clinic. J Exp Med, 2010,207(13):2781-2784.
[15] 国家卫生部. 医疗技术临床应用管理办法. 2009. Chinese Ministry of Public Health. Management Practices of the Clinical Application of Medical Technology. 2009.
[16] 中国食品与药品管理局. 人体细胞治疗研究和制剂质量控制技术指导原则. 2003. State Food and Drug Administration. Human Cell Therapy Research and Quality Control Guidelines of the Preparation. 2003.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
